The present invention refers to a combination of a TGF-beta inhibitor selected from the group consisting of an ALK-5 inhibitor, a neutralizing pan-anti-TGF-beta antibody, a neutralizing antibody against TGF-beta-1, or/and -2, or/and -3, a neutralizing anti-TGF-beta receptor type I or/and type II or/and type III antibody or binding fragments thereof with IL-2 and GM-CSF for use in a method of treating a malignant tumor in a patient. The invention is further directed to a pharmaceutical composition comprising the combination of the present invention, wherein the combination of compounds as well as the pharmaceutical composition are administered intratumorally. The combination as well as the pharmaceutical composition further comprise optionally an inhibitor of TGF-beta synthesis.